Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy
Aim of the work: To evaluate the hearing function in systemic lupus erythematosus (SLE) patients and assess the impact of chronic use of hydroxychloroquine (HCQ). Patients and methods: This study was conducted on 48 SLE patients and 12 matched controls. The SLE disease activity index (SLEDAI) was as...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/df9ad106414b42c582fff27932f3726a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Aim of the work: To evaluate the hearing function in systemic lupus erythematosus (SLE) patients and assess the impact of chronic use of hydroxychloroquine (HCQ). Patients and methods: This study was conducted on 48 SLE patients and 12 matched controls. The SLE disease activity index (SLEDAI) was assessed. Otological manifestations and extended high frequency audiometry were assessed. SLE patients were divided into those receiving HCQ (n = 36) and those not (n = 12). Results: The mean age of the patients was 39.5 ± 9.7 years, 40 females and 8 males, median disease duration was 7 (1.5–20) years. The median (interquartile range) SLEDAI was 4 (2.75). The median daily dose of those receiving HCQ was 400 mg. There was a significant difference regarding patients reported otological manifestations such as tinnitus (p = 0.02), vertigo (p = 0.002) and hearing impairment (p = 0.04) compared to controls but not for deafness or ear buzzing in one or both ears. There was a significant decrease in the hearing threshold frequencies between patients and controls (p < 0.001). Those receiving HCQ showed more hearing impairment at frequency 9000 and 20,000 Hz than those not (p = 0.004, p < 0.001 respectively). The otological manifestations were comparable between those receiving HCQ and those not. There was no difference between those receiving 400 mg/day (n = 31) HCQ and those receiving 200 mg/day (n = 5) Conclusion: Otological symptoms and sensorineural hearing loss are frequent among SLE patients. Chronic administration of HCQ may have an ototoxic effect. |
|---|